Filter articles using the following links

GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel

GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France

GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France

GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2 Million

GenSight Biologics Announces Successful Fundraising Amounting to Nearly €2 Million

GenSight Biologics announces regulatory authorizations for Individual Patient Expanded Access treatment with GS010/LUMEVOQ® in the US

GenSight Biologics Reports Cash Position as of September 30, 2025

GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 3.7 Million

GenSight Biologics Reports Interim Financial Results for the First Half of 2025

GenSight Biologics Announces Successful Fundraising Amounting to Nearly EUR 3.7 Million